PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19740369-1 2009 Recent evidence suggests that heterogeneity in the age at onset could explain the inconsistent findings of association studies relating the dopamine transporter (DAT1) gene with alcohol and nicotine consumption. Nicotine 190-198 solute carrier family 6 member 3 Homo sapiens 162-166 21315807-0 2011 The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Nicotine 99-107 solute carrier family 6 member 3 Homo sapiens 27-49 20074615-0 2010 Nicotine stimulates transcriptional activity of the human dopamine transporter gene. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 58-78 20074615-1 2010 Nicotine modulates dopaminergic activity in the central nervous system by acting on the reuptake system, including the dopamine transporter (DAT), although precisely remains unclear. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 119-139 20074615-1 2010 Nicotine modulates dopaminergic activity in the central nervous system by acting on the reuptake system, including the dopamine transporter (DAT), although precisely remains unclear. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 141-144 20074615-2 2010 Here we investigated the effect of nicotine on the transcriptional regulation of the human DAT (hDAT) gene by conducting luciferase reporter assays. Nicotine 35-43 solute carrier family 6 member 3 Homo sapiens 91-94 20074615-2 2010 Here we investigated the effect of nicotine on the transcriptional regulation of the human DAT (hDAT) gene by conducting luciferase reporter assays. Nicotine 35-43 solute carrier family 6 member 3 Homo sapiens 96-100 20074615-3 2010 Nicotine enhanced the transcription of hDAT gene constructs in transiently transfected SK-N-SH cells. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 39-43 20074615-6 2010 Deletion of intron 1, known as a silencer element of the hDAT gene, abolished nicotine"s stimulatory effect. Nicotine 78-86 solute carrier family 6 member 3 Homo sapiens 57-61 20074615-8 2010 These results suggest a nicotinic cholinergic mechanism to be involved in the nicotine-induced up-regulation of DAT gene expression. Nicotine 78-86 solute carrier family 6 member 3 Homo sapiens 112-115 17264803-1 2007 OBJECTIVES: To examine the association between polymorphisms in the dopamine transporter gene (SLC6A3, DAT1) and treatment outcome in smokers attempting to quit using either nicotine replacement therapy or bupropion. Nicotine 174-182 solute carrier family 6 member 3 Homo sapiens 68-88 19128199-0 2008 Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. Nicotine 68-76 solute carrier family 6 member 3 Homo sapiens 12-32 19128199-3 2008 Other drugs of abuse such as nicotine, ethanol, heroin and morphine interact with the DAT in more indirect ways. Nicotine 29-37 solute carrier family 6 member 3 Homo sapiens 86-89 18579413-6 2008 Lower DAT, but not D2R, in putamen and caudate were associated with poorer performance on multiple neuropsychological tests, corrected for the effects of age, education, intelligence, mood, and nicotine use. Nicotine 194-202 solute carrier family 6 member 3 Homo sapiens 6-9 18416663-7 2008 Nicotine seems to lower DAT availability such as stimulant medication; this may explain the high percentage of smokers among patients with ADHD. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 24-27 19451839-0 2009 Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson"s disease: an observational study. Nicotine 57-65 solute carrier family 6 member 3 Homo sapiens 0-20 19451839-2 2009 This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy. Nicotine 111-119 solute carrier family 6 member 3 Homo sapiens 54-74 19451839-9 2009 CONCLUSION: This observational study emphasizes a potential effect of nicotine therapy on striatal dopamine transporter density, which may be interpreted as direct pharmacological effect or deceleration of neuronal loss. Nicotine 70-78 solute carrier family 6 member 3 Homo sapiens 99-119 17427187-12 2007 These findings indicate that in the context of a multifactorial model, haplotypes in the 3" region of DAT1 influence the propensity of young women to initiate smoking as well as the severity of nicotine dependence once the habit is established. Nicotine 194-202 solute carrier family 6 member 3 Homo sapiens 102-106 17427187-13 2007 A haplotype in the 3" untranslated region of DAT1 modifies the effect of lifetime traumatic experience on the severity of nicotine dependence. Nicotine 122-130 solute carrier family 6 member 3 Homo sapiens 45-49 17264803-1 2007 OBJECTIVES: To examine the association between polymorphisms in the dopamine transporter gene (SLC6A3, DAT1) and treatment outcome in smokers attempting to quit using either nicotine replacement therapy or bupropion. Nicotine 174-182 solute carrier family 6 member 3 Homo sapiens 95-101 14685824-0 2004 Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence. Nicotine 114-122 solute carrier family 6 member 3 Homo sapiens 40-60 16882311-5 2006 The results showed that levels of striatal tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter, dopamine and nicotinic receptors were greater in nicotine-treated MPTP-lesioned primates than in lesioned animals not receiving nicotine. Nicotine 169-177 solute carrier family 6 member 3 Homo sapiens 65-85 16640111-5 2006 Nicotine seems to have a stimulant-like action on the DAT. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 54-57 14685824-1 2004 Previous studies suggested that a polymorphism in the dopamine transporter gene (SLC6A3) is associated with nicotine dependence and age of smoking onset, but the conclusion was controversial. Nicotine 108-116 solute carrier family 6 member 3 Homo sapiens 54-74 14685824-1 2004 Previous studies suggested that a polymorphism in the dopamine transporter gene (SLC6A3) is associated with nicotine dependence and age of smoking onset, but the conclusion was controversial. Nicotine 108-116 solute carrier family 6 member 3 Homo sapiens 81-87 14685824-2 2004 To detect the association of a G-->A polymorphism (NCBI dbSNP cluster ID: rs27072) in 3"-untranslated region of the SLC6A3 with nicotine dependence and early smoking onset, we recruited 253 sibships including 668 nicotine-dependent siblings from a rural district of China. Nicotine 131-139 solute carrier family 6 member 3 Homo sapiens 119-125 14685824-2 2004 To detect the association of a G-->A polymorphism (NCBI dbSNP cluster ID: rs27072) in 3"-untranslated region of the SLC6A3 with nicotine dependence and early smoking onset, we recruited 253 sibships including 668 nicotine-dependent siblings from a rural district of China. Nicotine 216-224 solute carrier family 6 member 3 Homo sapiens 119-125 14685824-6 2004 Although these findings are preliminary and need validation, the results suggest that a polymorphism in the SLC6A3 may play important roles in smoking onset, and there may be an interactive effect between the SLC6A3 and early smoking onset on modulating the susceptibility of nicotine dependence. Nicotine 276-284 solute carrier family 6 member 3 Homo sapiens 108-114 14685824-6 2004 Although these findings are preliminary and need validation, the results suggest that a polymorphism in the SLC6A3 may play important roles in smoking onset, and there may be an interactive effect between the SLC6A3 and early smoking onset on modulating the susceptibility of nicotine dependence. Nicotine 276-284 solute carrier family 6 member 3 Homo sapiens 209-215 8128835-6 1993 Nevertheless, they add to the growing body of evidence that the cholinergic system is involved in the control of attentional processes; and are substantiated by the findings of a second study examining the effects of an acute dose of nicotine on attentional and mnemonic performance in patients with DAT. Nicotine 234-242 solute carrier family 6 member 3 Homo sapiens 300-303 12135534-0 2002 Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Nicotine 25-33 solute carrier family 6 member 3 Homo sapiens 46-66 12135534-2 2002 Because stimulants have been shown to reduce primarily elevated DAT density in adults with ADHD, it can be suggested that nicotine acts in a similar way on striatal DAT as do stimulants. Nicotine 122-130 solute carrier family 6 member 3 Homo sapiens 64-67 12135534-2 2002 Because stimulants have been shown to reduce primarily elevated DAT density in adults with ADHD, it can be suggested that nicotine acts in a similar way on striatal DAT as do stimulants. Nicotine 122-130 solute carrier family 6 member 3 Homo sapiens 165-168 11979067-4 2002 Acutely administered nicotine failed to alter auditory P300, but increased the amplitudes of visual P300s in both DAT patient groups. Nicotine 21-29 solute carrier family 6 member 3 Homo sapiens 114-117 9925041-5 1999 This study provides preliminary evidence that the SLC6A3 gene may influence smoking initiation and nicotine dependence. Nicotine 99-107 solute carrier family 6 member 3 Homo sapiens 50-56 14624805-8 2003 Patients with ADHD and with a history of nicotine abuse both displayed lower values of DAT density in [99mTc]TRODAT-1 SPECT than non-smokers with ADHD. Nicotine 41-49 solute carrier family 6 member 3 Homo sapiens 87-90 11044890-11 2000 These findings suggest that the degree of DA transporter (DAT) occupancy contributes to the synergistic interaction between nicotine and cocaine or MP. Nicotine 124-132 solute carrier family 6 member 3 Homo sapiens 42-56 11044890-11 2000 These findings suggest that the degree of DA transporter (DAT) occupancy contributes to the synergistic interaction between nicotine and cocaine or MP. Nicotine 124-132 solute carrier family 6 member 3 Homo sapiens 58-61 2597885-1 1989 Nicotine in patients with dementia of the Alzheimer type (DAT) produced a significant and marked improvement in discriminative sensitivity and reaction times on a computerised test of attention and information processing. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 58-61 35464739-11 2022 Nicotine may act as a stimulant to inhibit the action of striatal DAT, increasing dopamine levels in the synaptic gap. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 66-69 1410164-1 1992 This single-blind, placebo controlled study reports on the effects of administering three acute doses of nicotine (0.4, 0.6 and 0.8 mg) subcutaneously to a group of Alzheimer"s disease (DAT) patients (n = 22), young adult controls (n = 24), and normal aged controls (n = 24). Nicotine 105-113 solute carrier family 6 member 3 Homo sapiens 186-189 1410164-9 1992 Despite the absence of change in memory functioning, these results demonstrate that DAT patients have significant perceptual and visual attentional deficits which are improved by nicotine administration. Nicotine 179-187 solute carrier family 6 member 3 Homo sapiens 84-87 34854936-0 2022 The role of the SLC6A3 3" UTR VNTR in nicotine effects on cognitive, affective, and motor function. Nicotine 38-46 solute carrier family 6 member 3 Homo sapiens 16-22 34854936-5 2022 OBJECTIVES: In this preregistered study, we hypothesized that 9R-carriers would be more responsive to nicotine due to genotype-related differences in DAT availability and resulting dopamine activity. Nicotine 102-110 solute carrier family 6 member 3 Homo sapiens 150-153 2597885-2 1989 Nicotine also improved the ability of DAT patients to detect a flickering light in a critical flicker fusion test. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 38-41 2597885-4 1989 Nicotine may therefore be of some value in treating deficits in attention and information processing in DAT patients. Nicotine 0-8 solute carrier family 6 member 3 Homo sapiens 104-107 27112968-7 2016 Cognitive modelling analysis using the prospect valence learning (PVL) model indicated that low DAT subjects" performance deteriorated following nicotine administration as indicated by an increased learning rate and a decreased response consistency. Nicotine 145-153 solute carrier family 6 member 3 Homo sapiens 96-99 27490263-10 2016 A significant multiplicative model interaction between nicotine dependence and the SLC6A3 gene score on smoking cessation was also observed (p = .03). Nicotine 55-63 solute carrier family 6 member 3 Homo sapiens 83-89 27490263-11 2016 CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: There is a significant multiplicative model interaction of SLC6A3 gene score and nicotine dependence on smoking cessation. Nicotine 122-130 solute carrier family 6 member 3 Homo sapiens 100-106 27112968-8 2016 Our results shed light on the neurochemistry underlying reward-based decision making in humans by demonstrating a significant interaction between nicotine and the DAT. Nicotine 146-154 solute carrier family 6 member 3 Homo sapiens 163-166 25526961-3 2014 RESULTS: Genotyping results suggested that nicotine dependence among current smokers homozygous for the SLC6A3 10r allele was lower than that of smokers carrying the minor alleles, and that the CYP2A6 polymorphism might mediate this association. Nicotine 43-51 solute carrier family 6 member 3 Homo sapiens 104-110 23009753-9 2013 We next determined how nicotine"s ability to reduce LIDs correlated with lesion-induced changes in the striatal dopamine transporter and (3)H-dopamine release in these two groups of monkeys. Nicotine 23-31 solute carrier family 6 member 3 Homo sapiens 112-132